This Viewpoint summarizes the role of the Patent Trial and Appeal Board (PTAB) in reforming the drug patent process to avoid erroneously granted patents; highlights how other reform efforts, such as the PREVAIL Act, actually weaken the PTAB; and suggests changes to strengthen the PTAB and promote generic availability and reduced health care costs.
